Видео ютуба по тегу John Vandermosten

Biotechnology Plays | John Vandermosten
Biotechnology Plays | John Vandermosten
In-depth about the drug development process with John Vandermosten
In-depth about the drug development process with John Vandermosten
John Vandermosten | CEO Money Episode 60
John Vandermosten | CEO Money Episode 60
John Vandermosten: Cancer Therapy Idea Merck
John Vandermosten: Cancer Therapy Idea Merck
Todd Davis & John Vandermosten Deliberate NIH Funding
Todd Davis & John Vandermosten Deliberate NIH Funding
Reviva Pharmaceuticals CEO Interview
Reviva Pharmaceuticals CEO Interview
Life Sciences Year in Review: Zacks' John Vandermosten speaks with CFO Allan Shaw
Life Sciences Year in Review: Zacks' John Vandermosten speaks with CFO Allan Shaw
John D. Vandermosten, Unboxing Biotech | The Jeff Crilley Show
John D. Vandermosten, Unboxing Biotech | The Jeff Crilley Show
John Vandermosten on the Supply of Capital in the Biotech Sector
John Vandermosten on the Supply of Capital in the Biotech Sector
John Vandermosten from Zacks Small Cap Research on CEO Money
John Vandermosten from Zacks Small Cap Research on CEO Money
BBS 03 10 25 John Vandermosten
BBS 03 10 25 John Vandermosten
Doug Fambrough from Dicerna Pharmaceuticals with John Vandermosten on CEO Money
Doug Fambrough from Dicerna Pharmaceuticals with John Vandermosten on CEO Money
John Vandermosten, a Senior Life Sciences Analyst, Talks Biotech IPO's on The Big Biz Show
John Vandermosten, a Senior Life Sciences Analyst, Talks Biotech IPO's on The Big Biz Show
John Vandermosten from Zacks Small Cap Research on CEO Money
John Vandermosten from Zacks Small Cap Research on CEO Money
Mike & Mary on the Big Biz Show speak with John Vandermosten about Dire Wolves & China
Mike & Mary on the Big Biz Show speak with John Vandermosten about Dire Wolves & China
John Vandermosten from Zacks Small Cap Research on CEO Money
John Vandermosten from Zacks Small Cap Research on CEO Money
James Oliviero from Checkpoint Therapeutics with Zacks' John Vandermosten on CEO Money
James Oliviero from Checkpoint Therapeutics with Zacks' John Vandermosten on CEO Money
Zacks analyst John Vandermosten bullish on Dyadic International's C1 gene expression platform
Zacks analyst John Vandermosten bullish on Dyadic International's C1 gene expression platform
Venture Capital trends in 2018 from Zacks analyst John Vandermosten
Venture Capital trends in 2018 from Zacks analyst John Vandermosten